Monday, Sep 7, 2015

Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress

Pivotal results for atezolizumab in urothelial bladder cancer and non-small cell lung cancer

Studies supporting regulatory submissions for three new medicines

Additional data from Genentech’s early cancer immunotherapy pipeline in solid tumors

South San Francisco, CA -- September 7, 2015 --

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 138 abstracts will be presented at this year's European Cancer Congress (ECC) from Sept. 25 – 29 in Vienna, Austria. Results will be presented from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder and skin cancer (alectinib, atezolizumab and cobimetinib, which recently received its first approval in Switzerland where it is marketed as Cotellic®). Building on its large portfolio of approved cancer medicines, these regulatory discussions represent significant progress for Genentech's pipeline in the fields of cancer immunotherapy and targeted medicines.


"With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancers."

In addition to data for alectinib, atezolizumab and cobimetinib, results will be presented across multiple tumor types from Genentech’s cancer immunotherapy and targeted medicines pipeline including CEA-IL2v (RG7813), IDO Inhibitor (GDC-0919) and vanucizumab (anti-Ang2/VEGF, RG7221). The table below contains key abstracts featuring Genentech medicines, including late breaking abstracts that will be presented during the Congress.

Follow Genentech on Twitter via @Genentech and keep up to date with the 2015 European Cancer Congress news and updates by using the hashtag #ECC2015.

Overview of key abstracts featuring Genentech medicines 


Abstract title

Abstract number

 Atezolizumab (MPDL3280A; anti-PDL1)


POPLAR: Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). J. Vansteenkiste et al.



BIRCH: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected non-small cell lung cancer (NSCLC). Benjamin Besse et al.


IMvigor210: Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). J. Rosenberg et al.


Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. G. Giaccone et al.



NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes. P. Schmid et al.

#14LBA (Proffered Paper Session)

Sunday, Sept. 27

9:15 AM CET


#16LBA (Proffered Paper Session)

Sunday, Sept. 27

9:35 AM CET


#21LBA (Proffered Paper Session)

Sunday, Sept. 27

10:40 AM CET


#513 (Poster Session)

Saturday, Sept. 26

4:45 PM CET


#3017 (Poster Discussion)

Sunday, Sept. 27

8:00 AM CET



Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC). F. Barlesi et al.

#3101 (Poster Session)

Sunday, Sept. 27

9:15 AM CET


Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. G. McArthur et al.

#25LBA (Proffered Paper Session)

Sunday, Sept. 27

12:10 PM CET

CEA-IL2v (RG7813)


Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine. J. Tabernero et al.

#505 (Proffered Paper Session)

Sunday, Sept. 27

6:30 PM CET

IDO Inhibitor



Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. A. Nayak et al.

#346 (Poster Session)

Sunday, Sept. 27

4:45 PM CET

Vanucizumab (anti-Ang2/VEGF, RG7221)


Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. T. Nayak et al.

#304 (Proffered Paper Session)

Saturday, Sept. 26

11:35 AM CET


About Genentech in Personalized Cancer Immunotherapy

For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to help his or her own immune system fight cancer. Genentech is studying more than 20 investigational medicines, seven of which are in clinical trials. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines. For more information visit

About Genentech

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit